ZyVersa Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ZyVersa Therapeutics generated cash of -$8,720,819, which is less than the previous year. Cash used in financing activities reached the amount of $5,956,294 last year. Net change in cash is therefore -$2,764,525.
Cash Flow
| 2020 | -5.10M | 0 | 4.56M |
|---|---|---|---|
| 2021 | -5.07M | 0 | 5.23M |
| 2022 | -1.49M | 0 | 1.86K |
| 2023 | -8.72M | 0 | 5.95M |
ZVSA Cash Flow Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Cash at beginning of period | 5.90M | 328.58K | 174.67K | 724.42K |
Operating activities | ||||
Net income | -98.29M | -14.04M | -8.08M | -12.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 10.4K | 9.86K | 10.4K | 10.4K |
Stock-based compensation expense | 1.19M | 3.52M | 4.14M | 3.83M |
| Deferred income tax benefit | 1.19M | 3.52M | 4.14M | 3.83M |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 |
Accounts payable | 2.40M | 6.61M | -311.86K | -601.47K |
Cash generated by operating activities | -8.72M | -1.49M | -5.07M | -5.10M |
Investing activities | ||||
Purchases Of Investments | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 |
Financing activities | ||||
Common Stock Issued | 18.11M | 1.86M | 0 | 3M |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | -10.70M | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -5.23M | -1.68M |
Cash used in financing activities | 5.95M | 1.86K | 5.23M | 4.56M |
Net Change In Cash | -2.76M | 370.74K | 153.91K | -549.75K |
Cash at end of period | 3.13M | 699.32K | 328.58K | 174.67K |
| Data source | Data source |